EPITHALON

Epithalon (also Epitalon, Ala-Glu-Asp-Gly) is a synthetic tetrapeptide from the Khavinson bioregulator program, researched primarily for telomerase activation, telomere elongation, and longevity effects. It is the most-studied Khavinson bioregulator and the compound with the most substantial long-term human cohort data in the cluster. Epithalon is not approved for any medical indication anywhere in the world. Regulatory status (August 2026): In April 2026 the FDA removed epithalon from its Category 2 "significant safety risks" bulk-substances list — a change the FDA attributed to the original nominations being withdrawn by the nominators, not a safety clearance, and one that did not add epithalon to Category 1 or authorize compounding. At its July 23–24, 2026 meeting the FDA's Pharmacy Compounding Advisory Committee voted to recommend epithalon for the 503A compounding list, but the vote is advisory and has not been finalized. A PCAC recommendation does not authorize compounding: pharmacies cannot legally compound epithalon under 503A until the FDA completes formal rulemaking, which is not expected before late 2027, and the agency may decline.

Sources: FDA Announces Removal of 12 Peptides from Category 2 (nominations withdrawn by the nominators) and Schedules PCAC Meetings, Orrick (legal analysis of the FDA notice), via Orrick Insights; PCAC July 23–24 2026 meeting outcome, FDA PCAC, via Buchanan Ingersoll / Clinical Peptide / NCPA / AJMC

What is Epithalon and how does the telomerase-activation mechanism work?

Epithalon (also Epitalon) is a synthetic Ala-Glu-Asp-Gly tetrapeptide proposed to enter cell nuclei and activate the catalytic subunit of telomerase (hTERT), restoring telomerase activity in somatic cells where it is normally silenced. Beyond the telomerase mechanism, the Khavinson framework proposes broader epigenetic effects through DNA-promoter binding. Telomerase activation theoretically counteracts the age-related telomere shortening associated with cellular senescence and the Hayflick limit.

Evidence level: preclinical extensive (in vitro telomerase, rodent lifespan); Khavinson-group human cohort studies; independent replication of telomere-elongation findings limited

What does the research show for Epithalon?

Preclinical studies have reported significant telomere elongation in cultured human cells, lifespan extension of approximately 24% in SHR mice, and reduced spontaneous tumor incidence in rodent models. Khavinson-group human cohort studies, with 10–15 year follow-up in elderly populations, have reported reduced all-cause mortality when Epithalon was combined with Thymalin — though these studies were non-blinded. A 2014 Khavinson study reported measurable changes in telomerase activity and reduced methylation of specific gene promoters in cultured human cells.

Evidence level: preclinical telomerase activation and lifespan extension; Khavinson-group human cohort studies with long follow-up (non-blinded); independent replication limited

How does Epithalon compare to other longevity-targeted peptides?

Epithalon is the most-studied bioregulator with the most direct mechanistic evidence (chromatin-binding, telomerase activation data) for the Khavinson epigenetic framework. Among longevity-targeted research compounds, Epithalon has the longest human follow-up data, though the data originates predominantly from the Khavinson research group.

What are the documented side effects of Epithalon?

Side effects in available preclinical and Khavinson-group human cohort data are mild — injection-site reactions are the most common report. Long-term safety in the Khavinson human cohort spans 10–15 years with the caveats that apply to non-blinded research. The telomerase-activation mechanism raises theoretical concerns about cancer risk (telomerase upregulation is implicated in many cancers), though the human cohort data has not surfaced increased cancer incidence — but the studies were not designed as oncology surveillance.

Evidence level: preclinical safety; Khavinson cohort safety (long follow-up, non-blinded); theoretical cancer concerns unaddressed at Western standards

What is the regulatory status of Epithalon?

Epithalon is not approved for any medical indication anywhere in the world as of August 2026. In April 2026 the FDA removed it from the Category 2 "significant safety risks" bulk-substances list — a step the FDA attributed to the original nominations being withdrawn by the nominators, which did not place epithalon in Category 1 or authorize compounding. At the July 23–24, 2026 PCAC meeting the committee voted to recommend epithalon for the 503A compounding list — one of six of seven peptides recommended over FDA reviewers' objections (the exact tally was reported inconsistently, roughly 7–5). That recommendation is advisory only; compounding remains unlawful under 503A until the FDA completes formal rulemaking, not expected before late 2027, and the agency retains discretion to decline. Current status in FDA peptide regulation 2025–2026 timeline.

Sources: FDA Announces Removal of 12 Peptides from Category 2 (nominations withdrawn by the nominators) and Schedules PCAC Meetings, Orrick (legal analysis of the FDA notice), via Orrick Insights; PCAC July 23–24 2026 meeting outcome, FDA PCAC, via Buchanan Ingersoll / Clinical Peptide / NCPA / AJMC

Why does Epithalon vendor verification matter?

Epithalon's short tetrapeptide structure (Ala-Glu-Asp-Gly) makes synthesis straightforward but identity verification matters because it shares amino acid composition with Cardiogen (Ala-Glu-Asp-Arg) and Cartalax (Ala-Glu-Asp). Mass spectrometry identity confirmation (expected MW 390.4 Da) distinguishes Epithalon from related Khavinson tetrapeptides. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Epithalon vendors?

Peptigrity collects independent third-party Certificates of Analysis for Epithalon from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. The lab test table above this section shows the cross-shop dataset. Methodology in how we calculate trust scores.

Frequently asked questions

What does Epithalon do?

Epithalon is proposed to activate telomerase, the enzyme that maintains telomere length, with preclinical evidence showing telomere elongation in cultured cells and lifespan extension in rodent models. Khavinson-group human cohort studies have reported reduced all-cause mortality when Epithalon was combined with other bioregulators. The evidence base is substantial in terms of patient-years but originates predominantly from one research group.

Is Epithalon legal to purchase?

Epithalon is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or any other major Western market. The April 2026 Category 2 removal (attributed to withdrawn nominations) and the July 2026 PCAC recommendation are steps toward a possible future compounding pathway, but neither authorizes compounding today — that requires FDA rulemaking not expected before late 2027. Country breakdown in peptide legal status guide.

When will the FDA decide on Epithalon?

The PCAC has already reviewed Epithalon: at its July 23–24, 2026 meeting it voted to recommend adding Epithalon to the 503A bulks list, over the objection of FDA's own reviewers. That recommendation is advisory, not a rule — the FDA must complete formal rulemaking (realistically 8–24 months, so late 2027 at the earliest) before any compounding is lawful, and it may decline. The April 2026 removal from Category 2 was attributed to the nominations being withdrawn by the nominators and did not authorize compounding. Track developments in FDA peptide regulation 2025–2026 timeline.

Sources: PCAC July 23–24 2026 meeting outcome, FDA PCAC, via Buchanan Ingersoll / Clinical Peptide / NCPA / AJMC; FDA Announces Removal of 12 Peptides from Category 2 (nominations withdrawn by the nominators) and Schedules PCAC Meetings, Orrick (legal analysis of the FDA notice), via Orrick Insights

Does Epithalon increase cancer risk?

Telomerase activation is theoretically a cancer-related mechanism — telomerase upregulation is implicated in many cancers — but Khavinson-group human cohort data has not surfaced increased cancer incidence over 10–15 year follow-up. However, those studies were not designed as oncology surveillance and the theoretical concern remains unaddressed at Western clinical standards. Anyone considering Epithalon should consult a licensed physician about the underlying mechanism biology.

How can I verify an Epithalon vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation (expected MW 390.4 Da). Mass spec is essential because Epithalon shares amino acid composition with related Khavinson tetrapeptides. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend an Epithalon dose?

No. Epithalon is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Khavinson-protocol dosing varies by research context. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. Epithalon is not approved by the FDA or any major Western regulator for human use, though it was removed from Category 2 of the FDA 503A bulk substances list in April 2026 and is scheduled for PCAC review in July 2026. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.